Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

Sponsor
Novo Nordisk A/S
Study ID
NCT02877355
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • semaglutide — DRUG
    All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days

Study Details

This trial is conducted in Europe. The aim of this trial is, to investigate the effect of upper gastrointestinal disease on the pharmacokinetics (the exposure of the trial drug in the body) of oral semaglutide in subjects with type 2 diabetes.

Key Dates

Start date
Aug 22, 2016
Status verified
Apr 2019
Primary completion
Nov 24, 2017
Completion
Nov 24, 2017

Study Design

Enrollment
55 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide

Primary Outcome Measure

Area under the semaglutide plasma concentration-time curve [ Time Frame: From 0 to 24 hours after the 10th dosing ]

Related Studies